TP Orthodontics competitors

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

Experienced Chief Executive Officer with a demonstrated history of working in the aesthetic, health care, and pharmaceutical industries. Strong legal and business professional skilled in Strategic Planning, Enhanced Valuation Strategies, M&A Activities, Intellectual Property and Brand Protection and Medical Compliance.